Bernadette Jeremiasse, Ravian L van Ineveld, Veerle Bok, Michiel Kleinnijenhuis, Sam de Blank, Maria Alieva, Hannah R Johnson, Esmée J van Vliet, Amber L Zeeman, Lianne M Wellens, Gerard Llibre-Palomar, Mario Barrera Román, Alessia Di Maggio, Johanna F Dekkers, Sabrina Oliveira, Alexander L Vahrmeijer, Jan J Molenaar, Marc Hwa Wijnen, Alida Fw van der Steeg, Ellen J Wehrens, Anne C Rios
{"title":"A multispectral 3D live organoid imaging platform to screen probes for fluorescence guided surgery.","authors":"Bernadette Jeremiasse, Ravian L van Ineveld, Veerle Bok, Michiel Kleinnijenhuis, Sam de Blank, Maria Alieva, Hannah R Johnson, Esmée J van Vliet, Amber L Zeeman, Lianne M Wellens, Gerard Llibre-Palomar, Mario Barrera Román, Alessia Di Maggio, Johanna F Dekkers, Sabrina Oliveira, Alexander L Vahrmeijer, Jan J Molenaar, Marc Hwa Wijnen, Alida Fw van der Steeg, Ellen J Wehrens, Anne C Rios","doi":"10.1038/s44321-024-00084-4","DOIUrl":null,"url":null,"abstract":"<p><p>Achieving complete tumor resection is challenging and can be improved by real-time fluorescence-guided surgery with molecular-targeted probes. However, pre-clinical identification and validation of probes presents a lengthy process that is traditionally performed in animal models and further hampered by inter- and intra-tumoral heterogeneity in target expression. To screen multiple probes at patient scale, we developed a multispectral real-time 3D imaging platform that implements organoid technology to effectively model patient tumor heterogeneity and, importantly, healthy human tissue binding.</p>","PeriodicalId":11597,"journal":{"name":"EMBO Molecular Medicine","volume":" ","pages":"1495-1514"},"PeriodicalIF":9.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251264/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMBO Molecular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s44321-024-00084-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Achieving complete tumor resection is challenging and can be improved by real-time fluorescence-guided surgery with molecular-targeted probes. However, pre-clinical identification and validation of probes presents a lengthy process that is traditionally performed in animal models and further hampered by inter- and intra-tumoral heterogeneity in target expression. To screen multiple probes at patient scale, we developed a multispectral real-time 3D imaging platform that implements organoid technology to effectively model patient tumor heterogeneity and, importantly, healthy human tissue binding.
期刊介绍:
EMBO Molecular Medicine is an open access journal in the field of experimental medicine, dedicated to science at the interface between clinical research and basic life sciences. In addition to human data, we welcome original studies performed in cells and/or animals provided they demonstrate human disease relevance.
To enhance and better specify our commitment to precision medicine, we have expanded the scope of EMM and call for contributions in the following fields:
Environmental health and medicine, in particular studies in the field of environmental medicine in its functional and mechanistic aspects (exposome studies, toxicology, biomarkers, modeling, and intervention).
Clinical studies and case reports - Human clinical studies providing decisive clues how to control a given disease (epidemiological, pathophysiological, therapeutic, and vaccine studies). Case reports supporting hypothesis-driven research on the disease.
Biomedical technologies - Studies that present innovative materials, tools, devices, and technologies with direct translational potential and applicability (imaging technologies, drug delivery systems, tissue engineering, and AI)